Dendritic cells generated in vivo by a chimeric hematopoietic growth factor, progenipoietin-4, demonstrate potent immunological function

Vaccine

Volumn 19, Issue 27, 2001, Pages 3710-3719

  Ishioka, Glenn Y ^a   Fikes, John ^a   Qin, Mingsheng ^a   Gianfrani, Carmen ^a   Chesnut, Robert W ^a   Kahn, Larry E ^b   Streeter, Philip R ^b   Woulfe, Susan L ^b   Sette, Alessandro ^a  

^a Epimmune   (United States)

^b PFIZER INC   (United States)

Author keywords

Cytotoxic T lymphocyte; Dendritic cell; Peptide

Indexed keywords

EPITOPE; HEMOPOIETIC GROWTH FACTOR; PROGENIPOIETIN 4; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIGEN PRESENTING CELL; ANTIGENICITY; ARTICLE; B LYMPHOCYTE; BONE MARROW CELL; CELL CLONE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HELPER CELL; IMMUNOGENICITY; IMMUNOREACTIVITY; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TRANSGENIC MOUSE;

ANIMALS; CELL DIVISION; CELL LINE; CLONE CELLS; DENDRITIC CELLS; EPITOPES, T-LYMPHOCYTE; HEMATOPOIETIC CELL GROWTH FACTORS; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED STRAINS; MICE, TRANSGENIC; PEPTIDES; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, HELPER-INDUCER; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0035859305     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(01)00102-5     Document Type: Article

References (25)

1. Progenipoietin-G promotes in vivo expansion of hematopoietic progenitor cells in mice and in nonhuman primates
2. Progenipoietins: Biological characterization of a family of dual agonists of fetal liver tyrosine kinase-3 and the granulocyte colony-stimulating factor receptor
3. Analysis of HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex
4. The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis
5. Utilization of MHC transgenic class I transgenic mice for development of minigene DNA vaccines encoding multiple HLA-restricted CTL epitopes
6. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides
7. Peptide binding to the most frequent HLA-A class I alleles measured by quantitative molecular binding assays
8. Characterization of an in situ IFN-α ELISA assay which is able to detect specific responses from freshly isolated splenocytes induced by DNA minigene immunization
9. Maturation stages of mouse dendritic cells in growth factor-dependent long-term cultures
10. Lymphoid dendritic cells are potent stimulators of the primary mixed lymphocyte reaction in mice
11. Presentation of exogenous protein antigens by dendritic cells to T cell clones. Intact protein is presented best by immature epidermal Langerhans cells
12. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor-α
13. The lymphoreticular system in triggering virus plus self-specific cytotoxic T cells: Evidence for T cell help
14. Helper activity is required for the in vivo generation of cytotoxic T lymphocytes
15. Distinct Ir genes for helper and killer cells in the cytotoxic response to H-Y antigen
16. Help for cytotoxic T cell responses is mediated by CD40 signaling
17. A conditioned dendritic cell can be a temporal bridge between a CD4+ T helper and a T killer cell
18. T cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions
19. Antigen presentation by splenic B cells: Resting B cells are ineffective, whereas activated B cells are effective accessory cells for T cell responses
20. Vaccination with MAGE-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma
21. Rapid generation of broad T cell immunity in humans after a single injection of mature dendritic cells
22. Bone marrow-derived dendritic cells pulsed with synthetic tumor peptides elicit protective and therapeutic antitumor immunity
23. Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo
24. Dendritic cells efficiently induce protective immunity
25. T cell activity after dendritic cell vaccination is dependent on both the type of antigen and the mode of delivery